Detailed analysis of outcomes and cost-effectiveness of R-CHOP and pola-R-CHP
| Treatment . | 2- and 5-Year outcomes . | Cost-effectiveness . | Incremental cost . | ICER ($/QALY) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2-y OS . | 2-y PFS . | 5-y OS . | 5-y PFS . | Life-years . | Effectiveness (QALYs) . | Incremental effectiveness . | Cost (2021 US dollars) . | |||
| R-CHOP | 88.4% | 70.2% | 77.4% | 62.7% | 11.37 | 10.89 | – | 342 833 | – | |
| Base-case (pola-R-CHP and R-CHOP have same 2- to 5-year relapse rates) | ||||||||||
| pola-R-CHP | 88.6% | 76.6% | 81.1% | 69.6% | 11.89 | 11.80 | 0.91 | 419 769 | 76 936 | 84 308 |
| Scenario 2 (pola-R-CHP decreases risk of relapse between 2 and 5 y) | ||||||||||
| pola-R-CHP | 88.6% | 76.6% | 84.3% | 75.1% | 12.60 | 12.40 | 1.51 | 377 192 | 45 784 | 30 321 |
| Scenario 3: pola-R-CHP merely delays inevitable relapses after 2 y | ||||||||||
| pola-R-CHP | 88.6% | 76.6% | 78.2% | 62.6% | 11.47 | 11.06 | 0.17 | 514 833 | 172 000 | 1 011 765 |
| Treatment . | 2- and 5-Year outcomes . | Cost-effectiveness . | Incremental cost . | ICER ($/QALY) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2-y OS . | 2-y PFS . | 5-y OS . | 5-y PFS . | Life-years . | Effectiveness (QALYs) . | Incremental effectiveness . | Cost (2021 US dollars) . | |||
| R-CHOP | 88.4% | 70.2% | 77.4% | 62.7% | 11.37 | 10.89 | – | 342 833 | – | |
| Base-case (pola-R-CHP and R-CHOP have same 2- to 5-year relapse rates) | ||||||||||
| pola-R-CHP | 88.6% | 76.6% | 81.1% | 69.6% | 11.89 | 11.80 | 0.91 | 419 769 | 76 936 | 84 308 |
| Scenario 2 (pola-R-CHP decreases risk of relapse between 2 and 5 y) | ||||||||||
| pola-R-CHP | 88.6% | 76.6% | 84.3% | 75.1% | 12.60 | 12.40 | 1.51 | 377 192 | 45 784 | 30 321 |
| Scenario 3: pola-R-CHP merely delays inevitable relapses after 2 y | ||||||||||
| pola-R-CHP | 88.6% | 76.6% | 78.2% | 62.6% | 11.47 | 11.06 | 0.17 | 514 833 | 172 000 | 1 011 765 |
First, the clinical outcomes (2- and 5-year OS and PFS) are displayed. Then effectiveness is displayed as life-years as well as QALYs. The costs displayed are the total lifetime costs related to DLBCL treatment for each strategy.